Skip to main content

Advertisement

SpringerLink
Log in

Glucose Transporter-1 (GLUT-1) Immunoreactivity in Benign, Premalignant and Malignant Lesions of the Gallbladder

  • Published:
Pathology & Oncology Research

Abstract

GLUT-1 is a transmembrane glucose transport protein that allows the facilitated transport of glucose into cells, normally expressed in tissues which depend mainly on glucose metabolism. Enhanced expression of GLUT-1 can also be found in a large spectrum of carcinomas. This study aimed to investigate GLUT-1 expression in gallbladder tissue: from normal tissue samples, hyperplasias, low-grade and high-grade dysplasias to gallbladder carcinomas. In all, 115 archived samples of gallbladder tissue from 68 patients, presented after cholecystectomy, were immunohistochemically stained for GLUT-1. According to the intensity of GLUT-1 immunoreactivity, samples were divided into negative (stained 0–10% of cells stained), positive with weak to moderate (10–50%) and positive with strong (>50%) GLUT-1 expression. The GLUT-1 immunoreactivity of the samples showed a characteristic increase from premalignant lesions to carcinomas. Normal gallbladder tissue samples did not express GLUT-1 (100%). Weak expression was shown only focally in hyperplasias, but to a greater extent with low-grade dysplasias (20%), high-grade dysplasias (40%) and carcinomas (51.8%). Normal gallbladder tissue is GLUT-1 negative. GLUT-1 expression in carcinoma tissue is significantly higher than in dysplastic lesions. Strong GLUT-1 expression indicates 100% specificity for detecting gallbladder carcinomas. Therefore, GLUT-1 is a candidate as a diagnostic as well as a tissue prognostic marker in gallbladder carcinoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

GLUT-1:

glucose transporter-1

No.:

number

vs.:

versus

References

  1. Dills WL (1993) Nutritional and physiological consequences of tumor glycolysis. Parasitology 107:S177–S186

    Article  PubMed  Google Scholar 

  2. Pessin JE, Bell GI (1992) Mammalian facilitative glucose transporter family: structure and molecular regulation. Ann Rev Physiol 54:911–930

    Article  CAS  Google Scholar 

  3. Ebert BL, Firth JD, Ratcliffe PJ (1995) Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J Biol Chem 270:29083–29089

    Article  PubMed  CAS  Google Scholar 

  4. Pardridge WM, Boado RJ, Farrell CR (1990) Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. J Biol Chem 265:18035–18040

    PubMed  CAS  Google Scholar 

  5. Gould GW, Holman GD (1993) The glucose transporter family: structure, function and tissue-specific expression. Biochem J 53:4204–4211

    Google Scholar 

  6. Froehner SC, Davies A, Baldwin SA, Lienhard GE (1998) The blood-nerve barrier is rich in glucose transporter. J Neurocytol 17:173–178

    Article  Google Scholar 

  7. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J (1996) Wide expression of the human erythrocyte glucose transporter Glut-1 in human cancers. Cancer Res 56:1164–1167

    PubMed  CAS  Google Scholar 

  8. Noguchi Y, Marat D, Saito A et al (1999) Expression of facilitative glucose transporters in gastric tumors. Hepato Gastroenterol 46:2683–2689

    CAS  Google Scholar 

  9. Reisser C, Eichhorn K, Herold-Mende C, Born AL, Bannasch P (1999) Expression of facilitative glucose transporter proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 80:194–198

    Article  PubMed  CAS  Google Scholar 

  10. Haber RS, Rathan A, Weiser KR et al (1998) GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83:34–40

    Article  PubMed  CAS  Google Scholar 

  11. Kalir T, Wang B, Goldfischer M et al (2002) Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 94:1078–1082

    Article  PubMed  CAS  Google Scholar 

  12. Ashton-Sager A, Paulino AFG, Afify AM (2006) GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. Appl Immunohistochem Mol Morphol 14:187–192

    Article  PubMed  CAS  Google Scholar 

  13. Chandan VS, Faquin WC, Wilbur DC, Khurana KK (2006) The utility of GLUT-1 immunolocalization in cell blocks: An adjunct to the fine needle aspiration diagnosis of cystic squamous lesions of the head and neck. Cancer 108:124–128

    Article  PubMed  Google Scholar 

  14. Ito H, Duxbury M, Zinner MJ, Ashley SW, Whang EE (2004) Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 136:548–556

    Article  PubMed  Google Scholar 

  15. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA, Hendrix MJC (1998) Role for glucose transporter 1 protein in human breast cancer. Pathol Oncol Res 4:115–120

    Article  PubMed  CAS  Google Scholar 

  16. Chandan VS, Faquin WC, Wilbur DC, Khurana KK (2006) The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. Cancer 108:331–336

    Article  PubMed  Google Scholar 

  17. Kim YW, Park YK, Yoon T, Lee SM (2002) Expression of GLUT-1 glucose transporter in gallbladder carcinomas. Hepatogastroenterol 49:907–911

    CAS  Google Scholar 

  18. Evans A, Bates V, Troy H et al (2008) GLUT-1 as a therapeutic target: increased chemoresistance and HIF-1 independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 61:377–393

    Article  PubMed  CAS  Google Scholar 

  19. Legan M, Luzar B, Marolt VF (2009) Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand J Gastroenterol 44:1101–1108

    Article  PubMed  Google Scholar 

  20. Cooper R, Sarioglu S, Sökmen S et al (2003) Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Brit J Cancer 89:870–876

    Article  PubMed  CAS  Google Scholar 

  21. Kanoh K, Shimura T, Tsutsumi S et al (2001) Significance of contracted cholecystitis lesions as high risk for gallbladder carcinogenesis. Cancer Lett 169:7–14

    Article  PubMed  CAS  Google Scholar 

  22. Tsuchida A, Itoi T, Aoki T, Koyanagi Y (2003) Carcinogenetic process in gallbladder mucosa with pancreaticobiliary maljunction. Oncol Rep 10:1693–1699

    PubMed  CAS  Google Scholar 

  23. Roa I, Araya JC, Villaseca M et al (1996) Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression. Gastroenterol 111:232–236

    Article  CAS  Google Scholar 

  24. Cantuaria G, Fagotti A, Ferrandina G et al (2001) GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92:1144–1150

    Article  PubMed  CAS  Google Scholar 

  25. Griffiths EA, Pritchard SA, Welch IM et al (2005) Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer 41:2792–2805

    Article  PubMed  CAS  Google Scholar 

  26. Airley R, Loncaster J, Davidson S et al (2001) Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7:928–934

    PubMed  CAS  Google Scholar 

  27. Miller JH, Mullin JM, McAvoy E, Kleinzeller A (1992) Polarity of transport of 2-deoxy-D-glucose and D-glucose by cultured renal epithelia (LLC-PK1). Biochim Biophys Acta 1110:209–217

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The study has been financially supported by Slovenian Research Agency, Research No. P3-0003.

Author information

Authors and Affiliations

  1. Institute of Histology and Embryology, Faculty of Medicine, University of Ljubljana, Korytkova 2, SI-1000, Ljubljana, Slovenia

    Mateja Legan, Špela Tevžič & Ana Tolar

  2. Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

    Boštjan Luzar & Vera Ferlan Marolt

Authors
  1. Mateja Legan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Špela Tevžič
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Tolar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Boštjan Luzar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vera Ferlan Marolt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mateja Legan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Legan, M., Tevžič, Š., Tolar, A. et al. Glucose Transporter-1 (GLUT-1) Immunoreactivity in Benign, Premalignant and Malignant Lesions of the Gallbladder. Pathol. Oncol. Res. 17, 61–66 (2011). https://doi.org/10.1007/s12253-010-9281-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-010-9281-7

Keywords

Search

Navigation